Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DFD-07 · 1 trial · 1 indication
Percent of patients with complete clearance of actinic keratosis (AK) lesions at the end of treatment (8 weeks)
| Arm | Type | Description |
|---|---|---|
| DFD-07 cream | EXPERIMENTAL | DFD-07 cream applied twice daily |
| Placebo cream | PLACEBO_COMPARATOR | Placebo cream applied twice daily |
| Name | Type | Description |
|---|---|---|
| DFD-07 Cream | DRUG | - |
| Placebo Cream | DRUG | - |
Inclusion Criteria: To be eligible for the study, the patients have to fulfil all of the following criteria at Visit 1: 1. Written informed consent has been signed and dated prior to any study related procedure or initiation of a wash out period 2. Skin type I, II or III according to Fitzpatrick 3...
DFD-07 is an investigational small molecule being developed for the treatment of actinic keratosis, a skin condition characterized by rough, scaly patches on the skin caused by sun damage. It is intended for use on the face and scalp. DFD-07 is currently in Phase 2 clinical development and is not yet approved.
DFD-07 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting clinical trials to evaluate the safety and efficacy of DFD-07 for actinic keratosis.
DFD-07 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 2 clinical trial for DFD-07 has been completed, and the drug is being studied for the treatment of actinic keratosis.
DFD-07 has been studied in a completed Phase 2 clinical trial with the identifier NCT02654717. This trial was an eight-week study of DFD-07 for actinic keratosis of the face and scalp. The trial enrolled 111 participants in Germany and was randomized, double-blind, and placebo-controlled.
DFD-07 is a distinct investigational drug candidate developed by Dr. Reddy's Laboratories Ltd. It is being studied specifically for actinic keratosis and is not known to be the same as any other marketed drug. Its unique chemical identity is part of its development as a new treatment option.